CytoCares
Latest round
- Series A
Last raised
- May 2023
Total raised
- $14M
Investors
- 5
About CytoCares
Based in Shanghai, China, and established in 2015, CytoCares is a biotechnology company that focused on the R&D of large molecule new drugs for tumour immunotherapy. Dr, Huaxing Zhu, the company's founder, established a listed biotechnology company, Novoprotein. CytoCares provides cell therapy products for haematological and solid tumours. It's the first product pipeline, CC312, is a tri-specific antibody based on CD28 co-stimulatory signalling. The tri-specific antibody, CC312, is performing the clinical phase 1 studies in China and the United States, which is intended to be developed for the treatment of B-cell malignant haematological tumours. CC312, is developed based on the TriTE platform, which is a T-cell bridger-based multi-drug platform based on CD3/CD28 dual-signal T-cell activation. Compared to CD19, CC312 has the greater capacity to induce the T-cell proliferation. And CC312 can be used for preventing tumour recurrence. Revenue is generated through licensing of biopharmaceutical candidates, strategic partnerships, CRO services, and reagent sales.
Who invested in CytoCares
5 investors across 1 round
See all investors in CytoCares
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 12, 2023
Amount
$14M
Investors
Questions about CytoCares
Who invested in CytoCares?
CytoCares has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CytoCares raised?
CytoCares has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did CytoCares last raise money?
CytoCares's most recent round on record is a Series A, in May 2023.
What does CytoCares do?
Based in Shanghai, China, and established in 2015, CytoCares is a biotechnology company that focused on the R&D of large molecule new drugs for tumour immunotherapy.
Where is CytoCares headquartered?
CytoCares is headquartered in Shanghai, China.
Which VCs invest in companies like CytoCares?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at CytoCares's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like CytoCares? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.